The Role Of FGF23 And Klotho In Cardiovascular Diseases For Patients With Chronic Kidney Disease

Chronic Kidney Disease(CKD)Patients affected by Mineral Bone Disorder(MBD)have a high risk of cardiovascular disease(CVD)mobidity and mortality risk that is poorly explained by traditional CVD risk factors.A better understanding of the biomarkers of CVD and their pathogenesis of CVD,such as left ventricular hypertrophy(LVH),heart failure,atrial fibrillation,and vascular calcification,may help with diagnosis and treatment of the organ damage that occured by CKD-MBD,thus improving their survival.Although recent drug treatment can make the cardiovascular complications in patients with end-stage renal disease is of certain clinical benefit,but it is still controversial.This review will discuss the basic and clinical research of FGF23(fibroblast growth factor23),Klotho protein,and state their role in pathogenesis and treatment of chronic kidney disease patients with heart failure,atrial fibrillation,vascular calcification and other aspects.